ERBB2 and breast carcinoma: This is important because emerging evidence suggests that different therapeutic approaches should be considered for HER2 heterogeneous breast carcinomas as they are less responsive to anti-HER2 therapies, display lower rates of pathologic complete response, and are associated with worse survival outcomes [27].